Technology evaluation: Rexin-G, Epeius Biotechnologies.
Publication
, Journal Article
Morse, M
Published in: Curr Opin Mol Ther
April 2005
Rexin-G is a 'pathotropic', tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene, under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. The therapy is currently undergoing phase I/II clinical trials.
Duke Scholars
Published In
Curr Opin Mol Ther
ISSN
1464-8431
Publication Date
April 2005
Volume
7
Issue
2
Start / End Page
164 / 169
Location
England
Related Subject Headings
- Retroviridae
- Pancreatic Neoplasms
- Neoplasm Metastasis
- Mice, Nude
- Mice
- Humans
- Genetic Vectors
- Genetic Therapy
- DNA
- Cyclins
Citation
APA
Chicago
ICMJE
MLA
NLM
Morse, M. (2005). Technology evaluation: Rexin-G, Epeius Biotechnologies. Curr Opin Mol Ther, 7(2), 164–169.
Morse, Michael. “Technology evaluation: Rexin-G, Epeius Biotechnologies.” Curr Opin Mol Ther 7, no. 2 (April 2005): 164–69.
Morse M. Technology evaluation: Rexin-G, Epeius Biotechnologies. Curr Opin Mol Ther. 2005 Apr;7(2):164–9.
Morse, Michael. “Technology evaluation: Rexin-G, Epeius Biotechnologies.” Curr Opin Mol Ther, vol. 7, no. 2, Apr. 2005, pp. 164–69.
Morse M. Technology evaluation: Rexin-G, Epeius Biotechnologies. Curr Opin Mol Ther. 2005 Apr;7(2):164–169.
Published In
Curr Opin Mol Ther
ISSN
1464-8431
Publication Date
April 2005
Volume
7
Issue
2
Start / End Page
164 / 169
Location
England
Related Subject Headings
- Retroviridae
- Pancreatic Neoplasms
- Neoplasm Metastasis
- Mice, Nude
- Mice
- Humans
- Genetic Vectors
- Genetic Therapy
- DNA
- Cyclins